G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma
Engineered T cells transiently expressing tumor-targeting receptors are an attractive form of
engineered T cell therapy as they carry no risk of insertional mutagenesis or long-term
adverse side-effects. However, multiple rounds of treatment are often required, increasing
patient discomfort and cost. To mitigate this, we sought to improve the antitumor activity of
transient engineered T cells by screening a panel of small molecules targeting epigenetic
regulators for their effect on T cell cytotoxicity. Using a model for engineered T cells …
engineered T cell therapy as they carry no risk of insertional mutagenesis or long-term
adverse side-effects. However, multiple rounds of treatment are often required, increasing
patient discomfort and cost. To mitigate this, we sought to improve the antitumor activity of
transient engineered T cells by screening a panel of small molecules targeting epigenetic
regulators for their effect on T cell cytotoxicity. Using a model for engineered T cells …
[PDF][PDF] G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered TCR-T cells against hepatocellular carcinoma
Engineered T cells transiently expressing tumor-targeting receptors are an attractive form of
engineered T cell therapy as they carry no risk of insertional mutagenesis or long-term
adverse side-effects. However, multiple rounds of treatment are often required, increasing
patient discomfort and cost. To mitigate this, we sought to improve the antitumor activity of
transient engineered T cells by screening a panel of small molecules targeting epigenetic
regulators for their effect on T cell cytotoxicity. Using a model for engineered T cells …
engineered T cell therapy as they carry no risk of insertional mutagenesis or long-term
adverse side-effects. However, multiple rounds of treatment are often required, increasing
patient discomfort and cost. To mitigate this, we sought to improve the antitumor activity of
transient engineered T cells by screening a panel of small molecules targeting epigenetic
regulators for their effect on T cell cytotoxicity. Using a model for engineered T cells …
以上显示的是最相近的搜索结果。 查看全部搜索结果